Fusion Pharmaceuticals Announces Poster Presentation at ASCO 2019

By May 16, 2019 No Comments

Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced today that it will present a poster at the 2019 American Society of Clinical Oncology meeting, which is being held from May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois. The abstract is available on the ASCO meeting website at

The Company will present a poster highlighting a Phase 1 study evaluating its lead candidate [225Ac]-FPI-1434, a radioimmunoconjugate consisting of a humanized monoclonal antibody that binds to the external domain of IGF-1R, a bifunctional chelate, proprietary linker, and the alpha-emitting radionuclide actinium-225 (Ac-225). The indium-111 analog, [111In]-FPI-1547, which contains the identical antibody and bifunctional chelate is used for patient selection and quantification of IGF-1R expressing targets prior to therapy.

The Phase 1 study has a primary objective of evaluating the safety and tolerability of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection in patients with advanced refractory solid tumors and to determine the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection. The study is currently enrolling patients in Canada.

Details of the poster presentation are below:

Abstract Title: A Phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.

Abstract Number for Publication: TPS3152

Session Title: Developmental Therapeutics and Tumor Biology (Nonimmuno)

Date: Saturday, June 1, 2019, 8:00 AM-11:00 AM CDT

Location: McCormick Place, Hall A

About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on targeted alpha therapy. Fusion exploits its unique expertise in linking medical isotopes to targeting molecules to create novel therapeutics. In addition to its lead program, [225Ac]-FPI-1434, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships. For more information, please visit or contact


Fusion Pharmaceuticals
Lynn Wick

KKH Advisors
Kimberly Ha